• Blog Innovation

    Daiichi Sankyo Sees Pillar of Growth in Next-Gen Biopharmaceuticals

    admin Posted on

    Daiichi Sankyo Co. Ltd. (TYO:4568) is making antibody drug conjugates (ADCs) and other next-generation biopharmaceuticals a pillar for medium- and……

    Please subscribe to read the full story.

    LEAVE A RESPONSE

    Your email address will not be published. Required fields are marked *

    You Might Also Like

    Recent Posts